

**Helicobacter pylori, Strain Hp A-14**

**Catalog No. NR-43673**

**Product Description:** *Helicobacter pylori* (*H. pylori*), strain Hp A-14 was isolated from gastric biopsy homogenate of a patient with gastritis in Ohio, USA.

**Lot<sup>1</sup>: 64136571**


**Manufacturing Date: 15APR2016**

TEST	SPECIFICATIONS	RESULTS
<b>Phenotypic Analysis</b> Cellular morphology Colony morphology <sup>2</sup>  Motility (wet mount) Biochemical characterization Catalase Oxidase Urease Nitrate reduction H <sub>2</sub> S (lead acetate paper) Hippurate hydrolysis Growth with 5% CO <sub>2</sub> Growth at 25°C Growth at 37°C Growth at 42°C Brucella albimi + 0.16% agar (growth control) Brucella albimi + 0.16% agar with 1% glycine Brucella albimi + 0.16% agar with 3.5% NaCl	Gram-negative rods Report results  Report results  Positive Positive Positive Negative Report results Negative Growth No growth Growth Report results Growth No growth No growth	Gram-negative rods Circular, low convex, entire, translucent and gray (Figure 1) Motile   Positive Positive Positive Negative Positive Negative Growth No growth Growth Growth Growth Growth No growth <sup>3</sup> No growth <sup>4</sup>
<b>Antibiotic Susceptibility Profile</b> BD BBL™ Sensi-Disc™ susceptibility test discs Metronidazole (80 µg) <sup>5</sup> Nalidixic acid (30 µg) <sup>6</sup>	Report results Report results	53 mm 8 mm
<b>Genotypic Analysis</b> Sequencing of 16S ribosomal RNA gene (~ 1390 base pairs)  Digital DNA-DNA hybridization (dDDH) <sup>7</sup>	≥ 99% sequence identity to <i>H. pylori</i> type strain (GenBank: AIHX01000070.1) > 70% agreement for species identification	99.7% sequence identity to <i>H. pylori</i> type strain (GenBank: AIHX01000070.1) <i>H. pylori</i> (91.8%)
<b>Confirmation of <i>H. pylori</i> by PCR Amplification of Extracted DNA</b> Positive control (16S ribosomal RNA gene) Negative control ( <i>H. acinonychis</i> ) <i>ureA</i> <i>ssaA</i>	Amplicon present No amplicon present Amplicon present Amplicon present	Amplicon present No amplicon present No amplicon present <sup>8</sup> Amplicon present
<b>Purity (post-freeze)</b> Microaerophilic growth <sup>9</sup>  Aerobic growth <sup>10,11</sup>	Growth consistent with expected colony morphology Growth consistent with expected colony morphology	Growth consistent with expected colony morphology Growth consistent with expected colony morphology
<b>Viability (post-freeze)<sup>2</sup></b>	Growth	Growth

<sup>1</sup>NR-43673 was produced by inoculation of the deposited material into Brucella broth. Broth inoculum was added to Columbia agar with 7% defibrinated horse blood, 5 µg/mL trimethoprim, 5 µg/mL vancomycin, 10 µg/mL cefsulodin and 2.5 µg/mL amphotericin B. The inoculated agar and broth were each grown for 4 days at 37°C in a microaerophilic atmosphere (~ 6-16% O<sub>2</sub> and 2-10% CO<sub>2</sub>). Colonies from the Columbia agar

- culture were suspended into the Brucella broth growth, and this biphasic culture was added to Columbia agar with 7% defibrinated horse blood, 5 µg/mL trimethoprim, 5 µg/mL vancomycin, 10 µg/mL cefsulodin and 2.5 µg/mL amphotericin B kolles, which were grown for 4 days 37°C in a microaerophilic atmosphere to produce this lot.
- <sup>2</sup>7 days on Columbia agar with 7% defibrinated horse blood, 5 µg/mL trimethoprim, 5 µg/mL vancomycin, 10 µg/mL cefsulodin and 2.5 µg/mL amphotericin B at 37°C in a microaerophilic atmosphere
- <sup>3</sup>Specifications for these tests were obtained from Bergey's Manual® of Systematic Bacteriology, 2<sup>nd</sup> ed., Volume 2, Part C, which indicates that growth may occur in up to 17% of strains.
- <sup>4</sup>Specifications for these tests were obtained from Bergey's Manual® of Systematic Bacteriology, 2<sup>nd</sup> ed., Volume 2, Part C, which indicates that growth may occur in 20% to 43% of strains.
- <sup>5</sup>Test performed using metronidazole 80 µg (MET-80, BBL™ catalog no. 231605)
- <sup>6</sup>Test performed using nalidixic acid 30 µg (NA-30, BBL™ catalog no. 231311)
- <sup>7</sup>Relatedness between bacterial strains has traditionally been determined using DDH. For additional information refer to Auch, A.F., et al. "Digital DNA-DNA Hybridization for Microbial Species Delineation by Means of Genome-to-Genome Sequence Comparison." *Stand Genomic Sci*, 2 (2010): 117-134, PubMed: 21304684.
- <sup>8</sup>NR-43673 failed to produce the ~380 base pair amplicon corresponding to the *H. pylori*-specific *ureA* gene. Sequence analysis of the *ureA* gene from *H. pylori*, Strain Hp A-14 (GenBank: AKOT00000000.1) identified sequence differences between the type strain on which the primers were based and the sequence of strain Hp A-14, in the binding site for the reverse primer, which negatively affected extension from this primer and resulted in no amplicon being generated.
- <sup>9</sup>Purity of this lot was assessed for 7 days on Tryptic Soy agar with 5% defibrinated sheep blood at 37°C in a microaerophilic atmosphere (~ 6-16% O<sub>2</sub> and 2-10% CO<sub>2</sub>).
- <sup>10</sup>Purity of this lot was assessed for 7 days on Tryptic Soy agar with 5% defibrinated sheep blood at 37°C in an aerobic atmosphere with 5% CO<sub>2</sub>.
- <sup>11</sup>*H. pylori* is known to show weak growth under aerobic conditions (Bury-Moné, S., et al. "Is *Helicobacter pylori* a True Microaerophile?" *Helicobacter* 11 (2006): 296-303. PubMed: 16882333.).

Figure 1: Colony Morphology



Date: 26 OCT 2016

Signature:

BEI Resources Authentication

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

